AstraZeneca posts 2025 Annual Report and AGM date

AstraZeneca PLC has published its 2025 Annual Report and Form 20-F information.

Rhea-AI Filing Summary

AstraZeneca PLC has published its 2025 Annual Report and Form 20-F information. The report is available on the company’s website and will also be submitted to the UK National Storage Mechanism for public inspection. Printed copies will be sent to shareholders in due course.

The company confirmed that its Annual General Meeting will take place on 9 April 2026. The Annual Report includes key regulated information such as principal risks and uncertainties, the directors’ responsibility statement for the financial statements and directors’ report, and a statement on related party transactions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AstraZeneca (AZN) announce in this Form 6-K filing?

AstraZeneca announced the publication of its 2025 Annual Report and Form 20-F information. The document includes key regulated disclosures and will be available on the company’s website and via the UK National Storage Mechanism for investor review.

Where can investors access AstraZeneca (AZN) 2025 Annual Report?

Investors can access AstraZeneca’s 2025 Annual Report on the company’s website, www.astrazeneca.com. A copy will also be submitted to the UK National Storage Mechanism, where it will be available for public inspection once processed by the facility.

When is AstraZeneca (AZN) holding its 2026 Annual General Meeting?

AstraZeneca plans to hold its Annual General Meeting on 9 April 2026. The company will publish and distribute the Notice of AGM and a Shareholders’ Circular to shareholders in due course ahead of the meeting for voting and governance purposes.

What regulated information is included in AstraZeneca (AZN) 2025 Annual Report?

The 2025 Annual Report includes principal risks and uncertainties facing the company, the directors’ responsibility statement for the financial statements and directors’ report, and a statement on related party transactions, satisfying key disclosure and transparency requirements for regulated information.

Does AstraZeneca (AZN) file its annual reports on Form 20-F or Form 40-F?

AstraZeneca files its annual reports under cover of Form 20-F. This reflects its status as a foreign private issuer with securities listed in the United States and aligns its annual reporting format with SEC requirements for such companies.

How can investors and media contact AstraZeneca (AZN)?

Investors can contact AstraZeneca’s Investor Relations team via contact details provided on the company’s website. Media representatives are directed to separate media contacts, also linked from the website, to handle press and communications inquiries efficiently.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 06:51 AM EST Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X      Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __      No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Annual Financial Report

24 February 2026

Annual Financial Report

AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2025 (the Annual Report).

A copy of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The Annual Report is also available on the Company's website www.astrazeneca.com.

The Annual Report will be dispatched to shareholders in due course.

The Company's Annual General Meeting (AGM) will take place on 9 April 2026. The Notice of AGM and Shareholders' Circular will be published and distributed to shareholders in due course.

EXPLANATORY NOTE

For the purposes of complying with the Disclosure and Transparency Rules, the Annual Report being submitted to the National Storage Mechanism contains the following regulated information in unedited form:

-     the principal risks and uncertainties facing the Company;

-     the Directors' responsibility statement made in respect of the Financial Statements and Directors' Report contained in the Annual Report; and

-     a statement regarding related party transactions.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 24 February 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary